INFLUENCE OF BLOCKADE AT SPECIFIC LEVELS OF THE COAGULATION CASCADE ON RESTENOSIS IN A RABBIT ATHEROSCLEROTIC FEMORAL-ARTERY INJURY MODEL

被引:196
作者
JANG, YS
GUZMAN, LA
LINCOFF, AM
GOTTSAUNERWOLF, M
FORUDI, F
HART, CE
COURTMAN, DW
EZBAN, M
ELLIS, SG
TOPOL, EJ
机构
[1] CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA
[2] CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, CLEVELAND, OH 44195 USA
[3] ZYMOGENET INC, SEATTLE, WA USA
[4] NOVO NORDISK AS, GENTOFTE, DENMARK
关键词
RESTENOSIS; COAGULATION; VASCULATURE; ANGIOPLASTY;
D O I
10.1161/01.CIR.92.10.3041
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background The relation among the coagulation cascade, its individual proteins, and the response to vascular injury is largely undefined. We have evaluated the effect of four probes that block specific levels of coagulation cascade on neointimal hyperplasia in the atherosclerotic rabbit arterial injury model. Methods and Results Focal femoral atherosclerosis was induced by air-desiccation injury and hypercholesterolemic diet in 48 New Zealand White rabbits, followed by balloon angioplasty. Active-site inactivated factor VIIa (DEGR-VIIa), which blocks the binding of factor VIIa to tissue factor, was administered (n=12 arteries) by intravenous bolus (1 mg/kg) at the time of balloon angioplasty and followed by infusion of 50 mu g . kg(-1). h(-1) for 3 days; for the control (n=13 arteries), 150 U heparin was injected as bolus and followed by infusion of saline at 50 mu L . kg(-1). min(-1). Recombinant tissue factor pathway inhibitor (TFPI), which binds factor X(a) and inhibits the tissue factor-factor VIIa complex and factor X(a), was given as a 1 mg/kg bolus followed by 15 mu g . kg(-1). min(-1) infusion for 3 days (n=17 arteries). Recombinant tick anticoagulant peptide (TAP; n=15 arteries) and hirudin (n=14 arteries), which block factor X(a) and thrombin, respectively, were administered as a 1 mg/kg bolus followed by 5 mu g . kg(-1). min(-1) infusion for 3 days. These three groups had their own controls (n=14 arteries). There were no differences among treatment groups in preangioplasty and postangioplasty minimal luminal diameter (MLD) by angiography. The mean MLD 21 days after balloon angioplasty was significantly different between control and DEGR-VIIa-treated groups (0.74+/-0.25 and 1.241+/-0.27 mm, respectively; P=.0001) and between the TFPI-treated group and others (0.88+/-0.21 mm for control, 0.97+/-0.22 mm for hirudin-treated, 0.98+/-0.14 mm for TAP-treated, and 1.32+/-0.21 mm for TFPI-treated arteries; P=.0001 by ANOVA). By quantitative histological analysis, the ratio of neointimal cross-sectional area compared with the area of internal elastic lamina in the DEGR-VIIa-treated group was significantly less than control (0.48+/-0.12 versus 0.67+/-0.12, P=.0001), and the ratio of neointimal cross-sectional area to the area demarcated by the internal elastic lamina of the TFPI-treated group was significantly reduced compared with the other groups (0.46+/-0.20 for TFPI-treated, 0.67+/-0.15 for hirudin-treated, 0.61+/-0.15 for TAP-treated, and 0.64+/-0.13 for control groups; P=.003). Conclusions Treatment with DEGR-VIIa or TFPI for 3 days in this rabbit atherosclerotic injury model reduced angiographic restenosis and decreased neointimal hyperplasia compared with controls. These findings highlight the importance of early initiators of the extrinsic coagulation pathway, especially factor VII and tissue factor. in the response to arterial injury.
引用
收藏
页码:3041 / 3050
页数:10
相关论文
共 65 条
[1]
DIFFERENTIAL EXPRESSION OF TISSUE FACTOR PROTEIN IN DIRECTIONAL ATHERECTOMY SPECIMENS FROM PATIENTS WITH STABLE AND UNSTABLE CORONARY SYNDROMES [J].
ANNEX, BH ;
DENNING, SM ;
CHANNON, KM ;
SKETCH, MH ;
STACK, RS ;
MORRISSEY, JH ;
PETERS, KG .
CIRCULATION, 1995, 91 (03) :619-622
[2]
HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL [J].
ANTMAN, EM .
CIRCULATION, 1994, 90 (04) :1624-1630
[3]
INITIATION OF COAGULATION BY TISSUE FACTOR [J].
BACH, RR .
CRC CRITICAL REVIEWS IN BIOCHEMISTRY, 1988, 23 (04) :339-368
[4]
THROMBIN IMMOBILIZED TO EXTRACELLULAR-MATRIX IS A POTENT MITOGEN FOR VASCULAR SMOOTH-MUSCLE CELLS - NONENZYMATIC MODE OF ACTION [J].
BARSHAVIT, R ;
BENEZRA, M ;
ELDOR, A ;
HYAM, E ;
FENTON, JW ;
WILNER, GD ;
VLODAVSKY, I .
CELL REGULATION, 1990, 1 (06) :453-463
[5]
BENEZRA M, 1993, BLOOD, V81, P3324
[6]
MINIMALLY MODIFIED LOW-DENSITY-LIPOPROTEIN STIMULATES MONOCYTE ENDOTHELIAL INTERACTIONS [J].
BERLINER, JA ;
TERRITO, MC ;
SEVANIAN, A ;
RAMIN, S ;
KIM, JA ;
BAMSHAD, B ;
ESTERSON, M ;
FOGELMAN, AM .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) :1260-1266
[7]
BLADBJERG EM, 1994, THROMB HAEMOSTASIS, V71, P755
[8]
BROZE GJ, 1988, BLOOD, V71, P335
[9]
ROLE OF HIGH-AFFINITY THROMBIN RECEPTORS IN POSTCLOTTING CELLULAR EFFECTS OF THROMBIN [J].
CARNEY, DH ;
REDIN, W ;
MCCROSKEY, L .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1992, 18 (01) :91-103
[10]
MITOGENIC ACTIVITY OF BLOOD COMPONENTS .1. THROMBIN AND PROTHROMBIN [J].
CHEN, LB ;
BUCHANAN, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (01) :131-135